Literature DB >> 14663375

Clinical evaluation using magnetic resonance imaging for patients with stage III cervical carcinoma treated by radiation alone in multicenter analysis: its usefulness and limitations in clinical practice.

Takeshi Kodaira1, Nobukazu Fuwa, Takafumi Toita, Yoshihito Nomoto, Kazuo Kuzuya, Kazuyuki Tachibana, Kazuhisa Furutani, Kazuhiko Ogawa.   

Abstract

To evaluate the ability of magnetic resonance imaging (MRI) to predict the clinical outcome, we perform retrospective multicenter analysis of patients with stage III disease treated with radiation alone. From three institutions, 80 patients with stage III disease diagnosed with MRI were entered in the study. Seventy-eight patients received intracavitary brachytherapy with external beam radiotherapy. Univariate and multivariate analyses were performed to identify the prognostic factors for overall survival (OAS), disease-free survival (DFS), pelvic control (PC), and distant metastasis-free survival (DMFS). The 5-year OAS, DFS, PC, and DMFS rates were 59.5%, 48.7, 74.2%, and 62.5%, respectively. Bilateral pelvic fixation to the pelvis (p = 0.001) and patient age 50 years or less (p < 0.0001) were significant adverse factors for OAS. As a function of DFS, these were positive lymph nodes (p = 0.02), bilateral fixation to the pelvis (p = 0.03), and younger patient age (p < 0.0001), respectively. Patient age 50 years or less proved to be the only significantly unfavorable factor for PC (p < 0.0001). Larger size/volume (p < 0.05), positive lymph nodes (p = 0.03), bilateral pelvic disease (p = 0.02), and younger patient age (p = 0.004) were significantly adverse factors for DMFS. Using multivariate analysis, patient age 50 years or less, disease with bilateral fixation, and calculated volume more than 100 ml proved to be significantly adverse factors for OAS and DFS. In the analysis of PC, only patient age 50 years or less was a significantly adverse factor (p = 0.0014, relative risk [RR] = 14.93). Bilateral fixation to the pelvis (p = 0.0055, RR = 4.032), positive lymph nodes (p = 0.0494, RR = 2.637), and large calculated volume (>100 ml; p = 0.0057, RR = 4.831) proved to be significantly adverse factors for DMFS. For patients with stage III disease, size/volume and lymph node status derived from MRI showed a significant correlation with the development of distant metastasis, but failed to predict locoregional control. In addition, size/volume analysis showed no apparent relationship with disease-free survival. For patients with stage III disease, MRI may provide beneficial information predicting distant metastasis, but not for local control.

Entities:  

Mesh:

Year:  2003        PMID: 14663375     DOI: 10.1097/01.coc.0000045811.97903.2A

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  4 in total

1.  Cervical cancer: MR imaging findings before, during, and after radiation therapy.

Authors:  Gulgun Engin
Journal:  Eur Radiol       Date:  2005-06-14       Impact factor: 5.315

2.  Assessment of tumor regression by consecutive pelvic magnetic resonance imaging and dose modification during high-dose-rate brachytherapy for carcinoma of the uterine cervix.

Authors:  Taek-Keun Nam; Byung-Sik Nah; Ho-Sun Choi; Woong-Ki Chung; Sung-Ja Ahn; Seok-Mo Kim; Ju-Young Song; Mi-Seon Yoon
Journal:  Cancer Res Treat       Date:  2005-06-30       Impact factor: 4.679

3.  Phase Ib study of durvalumab (MEDI4736) in combination with carbon-ion radiotherapy and weekly cisplatin for patients with locally advanced cervical cancer (DECISION study): study protocol for a prospective open-label single-arm study.

Authors:  Noriyuki Okonogi; Hirokazu Usui; Kazutoshi Murata; Makoto Hori; Tomoya Kurokawa; Tadami Fujiwara; Yasuhisa Fujii; Michiko Hanawa; Yohei Kawasaki; Yoko Hattori; Kazuko Suzuki; Kyoko Tsuyuki; Masaru Wakatsuki; Sumitaka Hasegawa; Shigeru Yamada; Hideki Hanaoka; Makio Shozu; Hiroshi Tsuji
Journal:  BMJ Open       Date:  2022-03-02       Impact factor: 2.692

4.  The Prognostic Value of Tumor Size, Volume and Tumor Volume Reduction Rate During Concurrent Chemoradiotherapy in Patients With Cervical Cancer.

Authors:  Chang Sun; Shubin Wang; Wenjing Ye; RanLin Wang; Mingyu Tan; Hanyi Zhang; Jie Zhou; Minglun Li; Lichun Wei; Peng Xu; Guiquan Zhu; Jinyi Lang; Shun Lu
Journal:  Front Oncol       Date:  2022-07-14       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.